NextCure, Inc.
NXTC
$9.63
-$0.01-0.10%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -21.47% | -14.62% | -10.35% | -19.16% | -28.63% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 65.47% | -26.27% | -21.12% | -20.00% | -13.91% |
| Operating Income | -65.47% | 26.27% | 21.12% | 20.00% | 13.91% |
| Income Before Tax | -74.03% | 35.84% | 19.80% | 19.31% | 13.75% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -74.03% | 35.84% | 19.80% | 19.31% | 13.75% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -74.03% | 35.84% | 19.80% | 19.31% | 13.75% |
| EBIT | -65.47% | 26.27% | 21.12% | 20.00% | 13.91% |
| EBITDA | -68.80% | 26.74% | 21.28% | 19.61% | 13.24% |
| EPS Basic | -70.83% | 36.08% | 20.10% | 19.70% | 14.19% |
| Normalized Basic EPS | -70.83% | 24.92% | 20.10% | 19.70% | 14.19% |
| EPS Diluted | -70.83% | 36.08% | 20.10% | 19.70% | 14.19% |
| Normalized Diluted EPS | -70.83% | 24.92% | 20.10% | 19.70% | 14.19% |
| Average Basic Shares Outstanding | 1.87% | 0.37% | 0.37% | 0.49% | 0.52% |
| Average Diluted Shares Outstanding | 1.87% | 0.37% | 0.37% | 0.49% | 0.52% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |